Abstract: A method of making a color filter array on a first substrate comprising the steps of: providing at least one transferable colorant layer on a second substrate and positioning such transferable layers in transferable relationship with but spaced a distance from the first substrate; and heating the second substrate sufficiently to simultaneously transfer the colorant materials from the heat transferable colorant layers to the first substrate. An etch process is used to form openings in the first colorant, into which subsequent colorants are deposited.

Abstract: A positive photosensitive resin composition comprising: (a) at least one polybenzoxazole precursor polymer having structure I or II; (b) at least one photosensitive compound selected from compounds described by structures III–V, (c) at least one solvent; and (d) optionally an adhesion promoter.

Abstract: A photoconductor having a charge generation layer and a charge transport layer, the charge transport layer having hydrazone or aryl amine charge transport molecules and also having as room light protective additives acetosol yellow 5GLS and tetraphenylcyclopentadienone or 9-fluorenone. Preferably the amount of the acetosol yellow is 2 to 4 percent by weight of the weight of the charge transfer layer and the ratio of weight between the acetosol yellow and the dienone or fluorenone is in the range of 1:1 to 1:3.

Abstract: A photosensitive layer contains an electron-transfer agent that makes use of a compound represented by the following general formula (1): wherein R1 through R4 are each independently selected from the group consisting of hydrogen, cyano, nitro, halogen, hydroxyl, alkyl, aryl, heterocyclic ring, ester, alkoxy, aralkyl, allyl, amide, amino, acyl, alkenyl, alkynyl, carboxyl, carbonyl, and carboxylic acid; X is selected from the group consisting of oxygen, sulfur, and ?C(CN)2; and W is a 4- to 8-membered ring.

Abstract: The invention provides liquid toner compositions in which the polymeric binder is chemically grown in the form of copolymeric binder particles dispersed in a liquid carrier. The polymeric binder includes one amphipathic copolymer comprising one or more S material portions and one or more D material portions, wherein the amphipathic copolymer comprises a polysiloxane moiety having molecular weight of at least about 500. Methods of making the liquid toner compositions are also provided.

Abstract: A process for fusing toner to paper. The toner fusing system for conducting this process includes a fuser roller consisting of a base, and a fusing surface layer that includes both a fluoroelastomer continuous phase, and also a discontinuous phase dispersed through the continuous phase in the form of domains.

Abstract: The present invention provides a photoresist composition and more particularly, a photoresist composition comprising a) a novolak resin, b) a diazide compound, and c) a solvent containing propylene glycol methyl ether acetate (PGMEA) and 2,2,4-triemthyl-1,3-penthanediolmonoisobutylate (TMPMB). The photoresist composition according to the invention has excellent coating uniformity and stain inhibitory properties after coating so that it can be easily applied to real industrial fields and it can improve working environments due to the reduction of amounts to be consumed, the decrease of time to be required for manufacture, etc. when manufactured on a large scale.

Abstract: A negative-type photosensitive resin compositions containing an epoxy compound are provided. These compositions use poly(p-vinylphenol) as the base resin and have good development performance when using an aqueous developer, such as tetramethylammonium hydroxide solution.

Abstract: A positive resist composition comprising (A) a resin that is decomposed by the action of an acid to increase solubility in an alkali developing solution and includes a specific repeating unit and (B) a compound that generates an acid upon irradiation of an actinic ray or radiation, and a pattern formation method using the positive resist composition.

Abstract: A resist curable resin material composed mainly of a curable prepolymer (for example, a photocurable resin material comprising a photosensitive prepolymer having an ethylenically unsaturated terminal group originating in an acrylic monomer (A), a compound having an ethylenically unsaturated group excluding the photosensitive prepolymer (B), and a photopolymerization initiator (C)) and a flame-retarding agent containing a hydrated metal compound and a brominated epoxy compound are mixed to produce a resist curable resin composition. Alternatively, the resist curable resin material described above and a hydrated metal compound surface-treated with a surface treating agent having an amphipathic property and a polarity are mixed to produce a resist curable resin composition.

Abstract: Negative type photosensitive resin compositions are provided. Such negative photosensitive resin compositions contain a novolac resin and a phenol-biphenylene resin as well as an epoxy compound. These resin compositions have excellent heat-impact resistance for the hardened resin material.

Abstract: A method of making a heat-sensitive lithographic printing plate precursor is disclosed which comprises the steps of (i) providing a web of a lithographic support having a hydrophilic surface; (ii) applying on the hydrophilic surface of the web a coating comprising a phenolic resin; (iii) drying the coating by supplying heat to the coated web; (iv) a cooling step wherein the web temperature is reduced at an average cooling rate which is higher than if the web would be kept under ambient conditions but not higher than 30° C./s; and (v) winding the precursor on a core or cutting the precursor into sheets. The cooling step provides a significant improvement of the aging behavior of the precursor. A stable sensitivity is obtained shortly after coating.

Abstract: A semiconductor manufacturing apparatus includes a liquid supplying section for supplying a liquid onto a stage for holding a wafer on which a resist film is formed; an exposing section for irradiating the resist film with exposing light through a mask with the liquid provided on the resist film; and a removing part for removing, from the liquid, a gas included in the liquid. Thus, the liquid from which the gas has been removed is provided on the resist film, and therefore, foams included in the liquid or formed during the exposure can be removed. Accordingly, exposure abnormality such as diffraction abnormality can be prevented, resulting in forming a resist pattern in a good shape.

Abstract: A method for making a heat-sensitive negative-working lithographic printing plate precursor is disclosed comprising the steps of (i) preparing a coating solution comprising hydrophobic thermoplastic polymer particles and a hydrophilic binder; (ii) applying said coating solution on a support having a hydrophilic surface or which is provided with a hydrophilic layer, thereby obtaining an image-recording layer; (iii) drying said image-recording layer; characterized in that said hydrophobic thermoplastic polymer particles have an average particle size in the range from 45 nm to 63 nm, and that the amount of said hydrophobic thermoplastic polymer particles in the image-recording layer is at least 70% by weight relative to the dried image-recording layer.

Abstract: Process for producing a tool insert for injection molding a microstructured part fabricated of a synthetic material, a metal or a ceramic material and which comprises an arrangement of microchannels and which further comprises an arrangement of through-going orifices extending in a substantially perpendicular manner with respect to the outer surface of the part.

Abstract: A composition for reducing development defects comprising an acidic composition containing, for example, a surfactant applied onto a chemically amplified photoresist coating formed on a substrate having a diameter of 8 inches or more. By this process, the surface of the resist is rendered hydrophilic and the formation of slightly soluble layer in a developer on the surface of the resist is prevented. In addition, by proper diffusion amount of acid from the composition for reducing development defects, the amount of reduction in thickness of the chemically amplified photoresist coating after development is increased by 10 ? to 500 ? in comparison with the case of not applying the composition for reducing development defects to form a resist pattern not having a deteriorated pattern profile such as T-top or round top.

Abstract: A silver halide photographic light-sensitive material and an aqueous coating composition, each containing at least one compound represented by formula (1): in which, in formula (1), A1 and A2 each independently represent a hydrogen atom or a fluorine atom, x and y each independently represent an integer of from 1 to 6, L1 and L2 each independently represent —CH2— or —CH2OCH2—, z represents the number of from 1 to 60, R1 and R2 each independently represent a hydrogen atom or a substituent, and R3, R4, R5 and R6 each independently represent a hydrogen atom, a methyl group or a hydroxymethyl group.

Abstract: Disclosed are a method for preparing grains of silver salt of an organic acid by reacting a solution containing silver ions and a solution containing an alkali metal salt of an organic acid, in which the reaction is performed in sealed mixing means and which comprises steps of supplying the solution containing silver ions into a reaction field solution before introduced into the sealed mixing means, and supplying the solution containing an alkali metal salt of an organic acid into the reaction field solution or sealed mixing means to which the solution containing silver ions has been supplied, etc. According to the present invention, high quality grains of silver salt of an organic acid can be efficiently produced at low cost.

Abstract: Methods are disclosed for the production of anti-self antibodies and antibody fragments, being antibodies or fragments of a particular species of mammal which bind self antigens of that species. Methods comprise providing a library of replicable genetic display packages (rgdps), such as filamentous phage, each rgdp displaying at its surface member of a specific binding pair which is an antibody or antibody fragment, and each rgdp containing nucleic acid sequence derived from a species of mammal. The nucleic acid sequence in each rgdp encodes a polypeptide chain which is a component part of the sbp member displayed at the surface of that rgdp. Anti-self antibody fragments are selected by binding with a self antigen from the said species of mammal. The displayed antibody fragments may be scFv, Fd, Fab or any other fragment which has the capability of binding antigen. Nucleic acid libraries used may be derived from a rearranged V-gene sequences of unimmunised mammal.

Abstract: A method for sequentially detecting multiple target nucleic acid fragments in a sample includes steps of adding a sample into a column having a test snare which has thereon multiple single strand capture DNA sequences; wherein each capture sequence binds specifically with one target nucleic acid fragment, and forms a double strand segment; washing out unbound target nucleic acid fragment; adding a first DNA probe, which has thereon a chemical label, to attach specifically to a probe binding site of the first target nucleic acid fragment; washing out unbound first probe; adding a triggering solution to trigger the chemical label; and detecting signals on the test snare for determining the first target nucleic acid fragment; subsequently, adding a second DNA probe to bind specifically to the second target nucleic acid fragment; washing, triggering and detecting signals for determining the second target nucleic acid fragment in the same manner.

Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

Abstract: Each gene in a group comprising many genes is cloned into an expression vector so that its gene product should be expressed as a fusion protein with a protein emitting self-fluorescence to construct a gene expression library. The gene expression library is introduced into cells of two groups to express the fusion proteins in the cells, and only one cell group is stimulated by a drug or the like. Then, cells in which the fusion proteins are localized in the nuclei or their nuclei are isolated from cells of the two groups, respectively. By comparing these cells, genes coding for proteins that are transported into the nuclei specifically in response to a certain stimulus when the stimulus is applied to the cells are retrieved.

Abstract: Chemically modified genomic sequences of genes associated with gene regulation, to oligonucleotides and/or PNA-oligomers for detecting the cytosine methylation state of genes associated with gene regulation which are directed against the sequence are disclosed. In addition, a method for ascertaining genetic and/or epigenetic parameters of genes associated with gene regulation is disclosed.

Abstract: The present invention relates to compositions and methods for the detection and characterization of nucleic acid sequences and variations in nucleic acid sequences. The present invention relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. For example, in some embodiments, a 5? nuclease activity from any of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof.

Abstract: The present invention is directed to a substrate having a plurality of microfeatures that provide a high surface area and are open to provide ready access to fluids and components therein. Methods of making the high surface area substrates are described and include generating microfeatures and/or microstructures on the surface of the substrate.

Abstract: Methods of using a genetic polymorphic variation in the human beta-1 adrenergic receptor gene as a drug response marker are presented. Determining the presence or absence of the A145G genetic variation in the human beta-1 adrenergic receptor gene is useful in predicting an individual's relative response to different antihypertensive drugs; optimizing antihypertensive treatment for an individual; selecting candidate human subjects for participation in clinical trials involving antihypertensive drugs; and, predicting the relative responses among a plurality of individuals to an antihypertensive drug.

Abstract: This invention relates to agents and conjugates that can be used to detect and isolate target components from complex mixtures such as nucleic acids from biological samples, cells from bodily fluids, and nascent proteins from translation reactions. Agents comprise a detectable moiety bound to a photoreactive moiety. Conjugates comprise agents coupled to substrates by covalent bounds which can be selectively cleaved with the administration of electromagnetic radiation. Targets substances labeled with detectable molecules can be easily identified and separated from a heterologous mixture of substances. Exposure of the conjugate to radiation releases the target in a functional form and completely unaltered. Using photocleavable molecular precursors as the conjugates, label can be incorporated into macromolecules, the nascent macromolecules isolated and the label completely removed.

Abstract: The invention is an oligonucleotide-based assay system and kit useful for sorting, detecting, and identifying analytes. The system utilizes complementary oligonucleotide pairs in which one oligonucleotide of each pair is immobilized to a solid substrate and the other oligonucleotide has an analyte binding agent attached to it. The different oligonucleotide pairs hybridize at substantially the same rate, have substantially the same Tm, have nucleotide sequences designed to minimize cross-hybridization between different pairs, and hybridize together relatively rapidly at ambient temperatures without detectable cross-hybridization.

Abstract: Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.

Abstract: A primer set used to screen a polynucleotide sample to detect and identify variants in the Cytochrome P450 isoenzyme 2D6 (CYP2D6) gene. A method of screening a polynucleotide sample to detect and identify the presence of one or more than one variant in the CYP2D6 gene in the sample. A method of predicting the potential for altered metabolism of a substance, including one or more than one pharmaceutical drug, by a first individual compared to a second control individual, where the substance is metabolized by the CYP2D6 isoenzyme, and where the second control individual is homozygous for the wild type allele of the CYP2D6*1, SEQ ID NO:1. A method of screening a population to detect and identify the presence of one or more than one variant in the CYP2D6 gene. A purified or isolated variant of SEQ ID NO:1. A purified or isolated variant of SEQ ID NO:3.

Abstract: A specimen testing device having a first panel with at least two apertures, a second panel with at least two apertures opposite the apertures in said first panel, a sheet disposed between the first and second panels for receiving a specimen through the apertures, the sheet in the apertures in said first panel having first, second and third portions disposed on opposite sides of a longitudinal axis of the apertures. First aperture covers are mounted on the first panel and overlie the apertures in the first panel. Second aperture covers are mounted on the second panel and overlie the apertures in the second panel. The first and second aperture covers in the first and second panels are movable independently of each other to expose the first, second and third portions of the sheet.

Abstract: The present invention provides methods to manipulate differentiation of a neuroblastoma cell line (IMR-32) such that predominant Nav expression is either Nav1.3 in IMR-32 cells exposed to retinoic acid or Nav1.7 in cells grown under non-differentiating conditions. The cells of the present invention are useful for the discovery of new compounds that modulate the function of either Nav1.3 and/or Nav1.7.

Abstract: Disclosed herein are molecules that include a deoxyribonucleic acid (DNA) covalently bonded to a protein and uses thereof.

Abstract: The invention relates to a method for detecting and supervising neurodegenerative diseases, which consists in detecting the presence of antibodies of the A-isotype and/or M-isotype which are directed against the antigens which are associated with these diseases. The invention also relates to a kit for the implementation of this method.

Abstract: The present invention relates to monoclonal antibodies that specifically bind buprenorphine and/or at least one metabolic product thereof. The present invention further relates to buprenorphine metabolite conjugates for the production of monoclonal antibodies that specifically bind buprenorphine and/or at least one metabolic product thereof and hybridoma cells that produce the monoclonal antibodies. The invention also relates to immunoassay methods for determining buprenorphine and/or one or more buprenorphine metabolites in a sample using the novel antibodies and conjugates of the present invention.

Abstract: 0Type II collagen degradation is measurable using a sandwich immunoassay in which a single antibody specific for the amino acid sequence EKGPDP is used to form each side of antibody-collagen fragment-antibody sandwich complexes and the amount of said complexes is measured.

Abstract: A method for detecting transferase activity of a sample includes contacting the sample with a substrate and at least one of a phosphate group donor and a phosphate group acceptor. The substrate includes a reporter compound and amino acids. A peptidase is added that cleaves a non-phosphorylated substrate at a first rate and a phosphorylated substrate and a second rate. The output of the reporter compound is detected. In a preferred embodiment, the transferase activity detected is a kinase activity. In another preferred embodiment, the transferase activity detected is a phosphatase activity. Also provided is a method of screening for alterations in a transferase reaction. Kits and peptide substrate are also provided for carrying out at least one of the methods of the invention.

Abstract: The present invention includes an assay useful for identifying inhibitors of Hepatitis C virus (HCV) activity. Particularly, the present invention is directed to a dual HCV assay useful for high throughput screening that quantifies both the amount of HCV RNA replication inhibitory activity associated with a test compound and the amount of cytotoxicity associated with that test compound. The present invention also includes compounds discovered using this assay, compositions containing such compounds and methods of treating Hepatitis C by the administration of such compounds. The present invention also includes reporter assays using enzymes associated with HCV RNA replication, as well as a cell line having ATTC Accession No. PTA-4583.

Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

Abstract: This invention relates to an isolated nucleic acid fragment encoding an isopentenyl diphosphate biosynthetic enzyme. The invention also relates to the construction of a chimeric gene encoding all or a portion of the isopentenyl diphosphate biosynthetic enzyme, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the isopentenyl diphosphate biosynthetic enzyme in a transformed host cell.

Abstract: A method for evaluating a compound to determine the relative or absolute therapeutic capability of a compound to pharmacologically inhibit ischemia induced activation of iPLA2? in an intact myocardium which comprises treating intact myocardium with a compound, inducing ischemia in the myocardium tissue and determining if there has been a change in expression of iPLA2?, its activity or in the iPLA2? regulating network and determining if there has been a change then that the compound is an anti-arrhythmia or myocardial salvage drug.

Abstract: The invention relates to processes for stabilizing the activity of an enzyme, comprising mixing a phosphine or phosphite with an oxidoreductase enzyme.

Abstract: Proteins modified by pharmacological preconditioning are provided. Compositions, methods and events for modulating these proteins and priming cells for preconditioning and inducing preconditioning in a cell, tissue or organ as well as methods for identifying new compositions and methods for such priming and induction are also provided. In addition, methods for diagnosing and monitoring preconditioning or ischemic, hypoxic, ischemic/reperfusion and hypoxic/reperfusion conditions or the ability of a cell, tissue or organ to survive injury by measuring modulation of one or more of these preconditioning proteins are provided.

Abstract: The present invention provides a method for assaying myeloperoxidase activity. In the assay, a sample containing myeloperoxidase or suspected of containing myeloperoxidase is contacted with substrate including serine, hydrogen peroxide, and a halide. If myeloperoxidase is present in the sample, serine is converted into glycolaldehyde, which is further converted into glycolate by a glycoaldehyde converting enzyme. The method then utilizes a cycling reaction system between glycolate and glyoxylate to generate a detectable signal that corresponds to the myeloperoxidase activity. Kits for assaying myeloperoxidases based on the same principle are also provided.

Abstract: The subject of the present invention is to provide a ?-lactam acylase protein having high activity, a gene coding for said ?-lactam acylase protein, a recombinant vector having said gene, a transformant containing said recombinant vector, and a method of producing a ?-lactam antibiotic such as amoxycillin using said ?-lactam acylase. A ?-lactam acylase gene of Stenotrophomonas maltophilia was cloned, the DNA base sequence and the amino acid sequence expected therefrom was determined, and a Stenotrophomonas ?-lactam acylase gene was obtained. This gene was found to code for a protein with a molecular weight of about 70 kDa and having ?-lactam acylase activity, and could efficiently produce amoxycillin without being inhibited by phenylacetic acid, etc. Furthermore, by modification of the amino acid sequence, a protein which can more efficiently produce amoxycillin could be obtained.

Abstract: A new class of ?2? subunits which function in calcium ion channels is described. This class is avian derived.

Abstract: PAK4 and JIK, both of which bind to MKK7 and directly phosphorylate MKK7, were found in the present invention. The present invention provides an inhibitor of c-Jun phosphorylation caused by JNK3 and a method for inhibiting the same, and an agent for preventing and/or treating a disorder attributable to c-Jun phosphorylation caused by JNK3 and a method for preventing and/or treating the same, all of which comprise inhibiting one member selected from the following: the binding of PAK4 to MKK7, the phosphorylation of MKK7 by PAK4, the binding of JIK to MKK7, and the phosphorylation of MKK7 by JIK. Further, the present invention provides a method for identifying a compound that inhibits the binding of PAK4 to MKK7, the phosphorylation of MKK7 caused by PAK4, the binding of JIK to MKK7, or the phosphorylation of MKK7 caused by JIK, as well as the compound obtained thereby.

Abstract: Provided is a method of producing a template DNA used for protein synthesis comprising a step of amplifying a linear double-stranded DNA by polymerase chain reaction (PCR), by using a reaction solution comprising a first double-stranded DNA fragment comprising a sequence coding for a protein or a portion thereof, a second double-stranded DNA fragment comprising a sequence overlapping with the 5? terminal region of the first DNA fragment, a third double-stranded DNA fragment comprising a sequence overlapping with the 3? terminal region of the first DNA fragment, a sense primer which anneals with the 5? terminal region of the second DNA fragment, and an anti-sense primer which anneals with the 3? terminal region of the third DNA fragment, wherein the second DNA fragment comprises a regulatory sequence for transcription and translation of a gene, and the concentrations of the second DNA fragment and the third DNA fragment in the reaction solution each range from 5 to 2,500 pmol/L.

Abstract: The present invention provides multiply deficient adenoviral vectors and complementing cell lines. Also provided are recombinants of the multiply deficient adenoviral vectors and a therapeutic method, particularly relating to gene therapy, vaccination, and the like, involving the use of such recombinants.

Abstract: The invention relates to a homoserine transsuccinylase, which exhibits reduced sensitivity towards L-methionine or SAM in comparison with a homoserine transsuccinylase wild-type enzyme, whereby the latter comprises an amino acid sequence containing a TyrGlnXaaThrPro sub-sequence, the Thr of said sub-sequence lying between positions 285 and 310 of the amino acid sequence and position 1 being filled by the starter methionine. The inventive homoserine transsuccinylase is characterized in that in comparison with the wild-type enzyme at least 2 amino acids are modified, said modification taking place in the Thr of the sub-sequence or in the C-terminal.